FDA to Review New Fetal Monitoring System
ST. LOUIS, Jan. 14 -- Mallinckrodt Inc. reported that its pre-market approval (PMA) application for a new infrared-based fetal oxygen saturation monitoring system called OxiSure has been accepted for filing by the US Food and Drug Administration. An advisory panel will review the application later this month and make a recommendation to the FDA as to whether the application should be approved.
Mallinckrodt's Oxisure system was designed to allow obstetricians to measure directly the arterial oxygenation of a fetus during labor and delivery. Using technology derived from the company's pulse oximeters, the system consists of a non-invasive fetal sensor containing red and IR light sources connected to a monitor that displays the percentage of oxygen in the fetal blood in real time.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024